pasireotide
Selected indexed studies
- Pasireotide-a novel somatostatin receptor ligand after 20 years of use. (Rev Endocr Metab Disord, 2022) [PMID:35067849]
- Pasireotide in the Personalized Treatment of Acromegaly. (Front Endocrinol (Lausanne), 2021) [PMID:33796079]
- Pasireotide for the treatment of acromegaly. (Expert Opin Pharmacother, 2016) [PMID:26808354]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pituitary acting drugs: cabergoline and pasireotide. (2022) pubmed
- Pasireotide-a novel somatostatin receptor ligand after 20 years of use. (2022) pubmed
- Pasireotide in the Personalized Treatment of Acromegaly. (2021) pubmed
- Pasireotide for the treatment of acromegaly. (2016) pubmed
- Management of pasireotide-induced hyperglycemia in patients with acromegaly: An experts' consensus statement. (2024) pubmed
- Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal. (2024) pubmed
- Current role of pasireotide in the treatment of acromegaly. (2024) pubmed
- Pasireotide in Acromegaly: A Review. (2015) pubmed
- How to Position Pasireotide LAR Treatment in Acromegaly. (2019) pubmed
- Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. (2022) pubmed